SCHEMBL3384546

SCHEMBL3384546

C=CCOC(=O)C(C[C@]1(O)[C@H]2CC[C@H]2[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 4/20 0.48
NR3C1 P04150 3/20 0.48
ALDH1A1 P00352 3/20 0.48
PGR P06401 2/20 0.48
ADRA1A P35348 1/20 0.48
HTR2B P41595 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.47
LMNA P02545 4/20 0.47
SERPINA6 P08185 3/20 0.47
CYP2C19 P33261 3/20 0.47
HSD17B10 Q99714 2/20 0.47
BLM P54132 2/20 0.47
TSHR P16473 2/20 0.47
HIF1A Q16665 2/20 0.47
CYP3A4 P08684 2/20 0.47
PMP22 Q01453 1/20 0.47
MEN1 O00255 3/20 0.47
MAPT P10636 3/20 0.47
KMT2A Q03164 3/20 0.47
ADORA3 P0DMS8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3356364 0.90 PSEN1 (0.54) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL3387445 0.82 SHBG (0.46) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL7793950 0.79 SHBG (0.54) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL3246003 0.78 SHBG (0.57) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL3385195 0.78 PGR (0.46) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL4907204 0.77 PSEN1 (0.48) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL3073418 0.76 SHBG (0.55) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL10783197 0.76 NR3C1 (0.55) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL10959339 0.76 PSEN1 (0.58) SHBGNR3C1ALDH1A1PGRADRA1A
SCHEMBL4907194 0.75 PSEN1 (0.47) SHBGNR3C1ALDH1A1PGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450476-B2 Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements RICHTER GEDEON NYRT. (HU) 2013-05-28 US claimed
EP-1831239-B1 A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 BETA, 7 BETA, 15 BETA, 16 BETA -BISMETHYLENE-17 ALPHA-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID LAMBDA-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS RICHTER GEDEON NYRT (HU) 2010-03-24 EP claimed
US-20080194812-A1 Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-08-14 US claimed
US-8450476-B2 Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements RICHTER GEDEON NYRT. (HU) 2013-05-28 US disclosed
WO-2010089053-A1 SOLVENT-FREE WATER-SOLUBLE SILANE-MODIFIED SILICATES COGNIS IP MANAGEMENT GMBH (DE) 2010-08-12 WO disclosed
EP-2216371-A1 Solvent-free water-soluble silane modified silicates Cognis IP Management GmbH (DE) 2010-08-11 EP disclosed
EP-1831239-B1 A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 BETA, 7 BETA, 15 BETA, 16 BETA -BISMETHYLENE-17 ALPHA-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID LAMBDA-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS RICHTER GEDEON NYRT (HU) 2010-03-24 EP disclosed
EP-2154111-A1 Water-soluble silicates and their utilisation Cognis IP Management GmbH (DE) 2010-02-17 EP disclosed
US-20080194812-A1 Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194812-A1 Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process CYP17A1, HSD17B7, HSD17B11 SHBG 57/4885NR3C1 121/4885ALDH1A1 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.